Geode Capital Management LLC Has $26.20 Million Stake in ACADIA Pharmaceuticals Inc. (ACAD)

Geode Capital Management LLC grew its stake in shares of ACADIA Pharmaceuticals Inc. (NASDAQ:ACAD) by 2.9% in the 4th quarter, according to the company in its most recent Form 13F filing with the Securities & Exchange Commission. The fund owned 869,977 shares of the biopharmaceutical company’s stock after purchasing an additional 24,847 shares during the period. Geode Capital Management LLC’s holdings in ACADIA Pharmaceuticals were worth $26,195,000 as of its most recent SEC filing.

Other hedge funds and other institutional investors also recently made changes to their positions in the company. Steward Partners Investment Advisory LLC purchased a new stake in shares of ACADIA Pharmaceuticals during the fourth quarter valued at $200,000. Zurcher Kantonalbank Zurich Cantonalbank lifted its holdings in shares of ACADIA Pharmaceuticals by 43.2% during the third quarter. Zurcher Kantonalbank Zurich Cantonalbank now owns 5,670 shares of the biopharmaceutical company’s stock valued at $214,000 after purchasing an additional 1,710 shares during the last quarter. State of Alaska Department of Revenue purchased a new stake in shares of ACADIA Pharmaceuticals during the fourth quarter valued at $219,000. Chicago Equity Partners LLC purchased a new stake in shares of ACADIA Pharmaceuticals during the fourth quarter valued at $237,000. Finally, Ladenburg Thalmann Financial Services Inc. lifted its holdings in shares of ACADIA Pharmaceuticals by 56.8% during the third quarter. Ladenburg Thalmann Financial Services Inc. now owns 6,509 shares of the biopharmaceutical company’s stock valued at $247,000 after purchasing an additional 2,358 shares during the last quarter. 96.24% of the stock is owned by institutional investors and hedge funds.

How to Become a New Pot Stock Millionaire

ACADIA Pharmaceuticals Inc. (ACAD) opened at $22.57 on Monday. ACADIA Pharmaceuticals Inc. has a 52-week low of $22.35 and a 52-week high of $41.20.

ACADIA Pharmaceuticals (NASDAQ:ACAD) last posted its quarterly earnings results on Tuesday, February 27th. The biopharmaceutical company reported ($0.55) earnings per share for the quarter, beating the consensus estimate of ($0.58) by $0.03. The firm had revenue of $43.56 million for the quarter, compared to analyst estimates of $45.30 million. ACADIA Pharmaceuticals had a negative return on equity of 73.02% and a negative net margin of 231.71%. sell-side analysts expect that ACADIA Pharmaceuticals Inc. will post -1.82 EPS for the current year.

In other news, Director Daniel B. Soland bought 7,000 shares of the company’s stock in a transaction on Thursday, March 1st. The shares were bought at an average cost of $23.91 per share, with a total value of $167,370.00. Following the transaction, the director now directly owns 2,000 shares in the company, valued at approximately $47,820. The acquisition was disclosed in a legal filing with the SEC, which can be accessed through this hyperlink. Also, Director Laura Brege sold 25,000 shares of the company’s stock in a transaction dated Tuesday, January 2nd. The stock was sold at an average price of $30.06, for a total value of $751,500.00. Following the completion of the transaction, the director now directly owns 15,000 shares in the company, valued at $450,900. The disclosure for this sale can be found here. Insiders have sold 135,879 shares of company stock worth $4,175,649 over the last three months. 22.25% of the stock is owned by insiders.

ACAD has been the subject of several analyst reports. BidaskClub raised ACADIA Pharmaceuticals from a “sell” rating to a “hold” rating in a report on Wednesday, December 27th. Zacks Investment Research downgraded ACADIA Pharmaceuticals from a “buy” rating to a “hold” rating in a report on Tuesday, January 2nd. Finally, ValuEngine lowered ACADIA Pharmaceuticals from a “sell” rating to a “strong sell” rating in a research report on Friday. Two equities research analysts have rated the stock with a sell rating, three have issued a hold rating and ten have given a buy rating to the company. ACADIA Pharmaceuticals currently has an average rating of “Buy” and a consensus price target of $49.50.

ILLEGAL ACTIVITY NOTICE: This report was posted by Ticker Report and is the sole property of of Ticker Report. If you are accessing this report on another site, it was illegally stolen and republished in violation of United States and international trademark and copyright laws. The legal version of this report can be viewed at https://www.tickerreport.com/banking-finance/3301491/geode-capital-management-llc-has-26-20-million-stake-in-acadia-pharmaceuticals-inc-acad.html.

ACADIA Pharmaceuticals Company Profile

ACADIA Pharmaceuticals Inc is a biopharmaceutical company. The Company is focused on the development and commercialization of medicines for central nervous system (CNS) disorders. Its lead drug candidate, NUPLAZID (pimavanserin), is used for the treatment of hallucinations and delusions associated with Parkinson’s disease psychosis (PD Psychosis).

Want to see what other hedge funds are holding ACAD? Visit HoldingsChannel.com to get the latest 13F filings and insider trades for ACADIA Pharmaceuticals Inc. (NASDAQ:ACAD).

Institutional Ownership by Quarter for ACADIA Pharmaceuticals (NASDAQ:ACAD)

Receive News & Ratings for ACADIA Pharmaceuticals Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for ACADIA Pharmaceuticals and related companies with MarketBeat.com's FREE daily email newsletter.

Latest News

Transcontinental  Upgraded to “Outperform” by Royal Bank of Canada
Transcontinental Upgraded to “Outperform” by Royal Bank of Canada
Mosaic Capital  Downgraded to Hold at Canaccord Genuity
Mosaic Capital Downgraded to Hold at Canaccord Genuity
Weibo  Upgraded by Zacks Investment Research to Buy
Weibo Upgraded by Zacks Investment Research to Buy
KeyCorp  Price Target Lowered to $24.00 at BMO Capital Markets
KeyCorp Price Target Lowered to $24.00 at BMO Capital Markets
Wolf Minerals  Sets New 52-Week Low at $2.30
Wolf Minerals Sets New 52-Week Low at $2.30
Omega Diagnostics Group  Trading 0% Higher
Omega Diagnostics Group Trading 0% Higher


© 2006-2018 Ticker Report. Google+.